Lurasidone (latuda®): an atypical antipsychotic.

Lurasidone is a new atypical antipsychotic that has demonstrated positive effects on psychosis, mood, and cognition. This improved efficacy and safety profile for the treatment of schizophrenia. Its overall tolerability profile seems to be comparable to the other atypical antipsychotics.

Use of famotidine in adult patients with end-stage renal disease: assessment of dosing and mental status changes.

Background: Famotidine dosage adjustment is required in patients with chronic kidney disease. Since recommendations on the degree of famotidine dose reduction vary between references, a chart review was conducted to evaluate the tolerability of varying famotidine doses in adults with end-stage renal disease (ESRD).

Methods: An assessment was made of famotidine doses prescribed to patients with ESRD over a 7-year period in a university hospital.